HIM
IBIO icon

Hillsdale Investment Management’s iBio IBIO Stock Holding History

Hillsdale Investment Management’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61 Buy
+32
New +$74 ﹤0.01% 653

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Hillsdale Investment Management's IBIO Position: Q1 2026 in Review

Hillsdale Investment Management opened a new position in iBio (IBIO) in Q1 2026: 32 shares worth $61. The stake represents ﹤0.01% of the portfolio and ranks #653 among its holdings.

52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

  • Hillsdale Investment Management held 32 shares of iBio worth $61 as of Q1 2026.
  • iBio was a new Hillsdale Investment Management position in Q1 2026.
  • iBio made up ﹤0.01% of Hillsdale Investment Management's portfolio in Q1 2026, its #653 holding.
  • 52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.